DTU Logo
Overview | 4-T | ACE | ADOPT | AFORRD | DREAM | EDIT | EXSCEL | FHS | GLINT | ISAT | LDS | NAVIGATOR | TECOS | UKPDS

Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research



Executive Committee (EC)

The EC is responsible for the overall management, oversight and reporting of the trial.

Robert Califf US Cardiologist (Chair)
Rury Holman UK Endocrinologist (Co-Chair)
Steve Haffner US Endocrinologist
John McMurray UK Cardiologist

Data Monitoring Committee (DMC)

The DMC ensure the safety of the trial participants by undertaking regular independent evaluation of trial safety data.

Antonio Gotto US Cardiologist (Chair)
Aldo Maggioni Italy Cardiologist
Eberhard Standl Germany Endocrinologist
Bernard Zinman Canada Endocrinologist
Joel Verter US Statistician

Steering Committee (SC)

The Steering Committee is comprised of lead investigators from participating countries and includes experts in cardiology and diabetes.  The main roles of the steering committee are to review and approve the study design, all protocol amendments, substudies, and study progress and to transmit critical information to individual investigators.

Study Sponsor

Novartis